Calibre Post Acute: Care Plan Deficiencies - NM
The case involved a resident with dementia, insomnia and major depressive disorder who had been taking the same 20-milligram daily dose of escitalopram since arriving at the facility in October 2024. Nearly 10 months later, the consultant pharmacist recommended evaluating the resident for a dose reduction.
The provider's response was brief: "Resident with good response, maintain current dose. Disagree with the pharmacist recommendation."
No clinical rationale followed.
Federal regulations require physicians to document their reasoning when declining pharmacist recommendations during monthly drug reviews. The missing justification could leave residents on unnecessarily high medication doses that increase risks of drug interactions and adverse side effects, inspectors noted.
The resident's medication history revealed a complex regimen. Along with escitalopram for depression, he received oxcarbazepine — initially prescribed as an anticonvulsant in October 2024, then discontinued in May 2025 and restarted the same day specifically for depression. He also took trazodone, first ordered in November 2024 as a sleep aid, then reordered in June 2025 for insomnia.
The pharmacist's July 28, 2025 recommendation came after the resident had maintained the same escitalopram dose for nearly a year. Such gradual dose reductions, known as GDRs, are standard practice to determine if residents still need their current medication levels.
During interviews, facility leaders acknowledged the oversight. The Director of Nursing confirmed on October 9 that the resident had been taking identical doses of both escitalopram and oxcarbazepine since his October 2024 admission. She verified that the pharmacist had recommended a gradual dose reduction for escitalopram and that the provider had declined without documenting clinical reasoning.
The Medical Director, interviewed five days later, explained that gradual dose reductions for antidepressants should be attempted when residents show no signs of depression. He confirmed that providers were expected to document clinical rationales when declining such recommendations.
The facility's failure extended beyond a single case. Inspectors reviewed three residents with depression and found documentation problems affected one of the three cases examined.
Monthly pharmacist reviews serve as a crucial safety net in nursing homes, where residents often take multiple medications that can interact dangerously. The consultant pharmacist acts as an independent check on prescribing patterns, identifying opportunities to reduce unnecessary medications or adjust doses based on residents' current conditions.
When physicians disagree with pharmacist recommendations, their documented reasoning becomes part of the resident's permanent medical record. This documentation helps future caregivers understand treatment decisions and ensures continuity of care if providers change.
The inspection report classified the violation as causing minimal harm or potential for actual harm to some residents. However, the deficient practice could result in residents receiving medications no longer necessary, potentially causing drug interactions or adverse side effects.
Escitalopram, the antidepressant in question, belongs to a class of drugs called selective serotonin reuptake inhibitors. While generally well-tolerated, these medications can cause side effects including nausea, sleep disturbances, and sexual dysfunction. In elderly residents with multiple medical conditions, unnecessary high doses may compound existing health problems.
The resident's case highlighted broader medication management challenges in long-term care. With multiple psychiatric medications — escitalopram for depression, oxcarbazepine repurposed from seizure prevention to depression treatment, and trazodone for sleep — careful monitoring becomes essential to prevent overmedication.
Inspectors found no evidence that the facility conducted the recommended dose evaluation or reassessed whether the resident still required the full 20-milligram daily dose nearly a year after starting treatment.
The violation occurred despite clear facility policies requiring physician documentation of rationales when declining pharmacist recommendations. The gap between policy and practice left the resident's medication regimen unchanged without proper medical justification.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Calibre Post Acute, LLC from 2025-11-18 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Calibre Post Acute, LLC in Las Cruces, NM was cited for violations during a health inspection on November 18, 2025.
Nearly 10 months later, the consultant pharmacist recommended evaluating the resident for a dose reduction.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.